Table 2.
Proportion of GLA:D™ participants with clinically important improvement by program location, baseline to 3-months (self-reported measures) and from baseline to program completion (physical measures).
| Metro (n = 289) | Metro-influenced (n = 100) | Urban (n = 60) | Rural (n = 105) | P-value | |
|---|---|---|---|---|---|
| Outcomes | Percent (95% Confidence Interval) | ||||
| Pain, HOOS/KOOS | 11.6 (8.2–16.0) | 18.0 (10.8–28.3) | 13.7 (6.5–26.6) | 14.0 (8.2–22.8) | 0.71 |
| Joint-related quality of life, HOOS/KOOS | 25.3 (20.6–30.7) | 23.2 (15.8–32.7) | 24.6 (15.2–37.3) | 28.6 (20.6–38.1) | 0.49 |
| Health-related quality of life (EQ-5D-5L) | 27.9 (23.0–33.4) | 23.2 (15.8–32.7) | 31.2 (20.6–44.1) | 23.2 (13.3–28.9) | 0.87 |
| 30-s chair stand (count) | 70.4 (64.0–76.0) | 75.7 (64.0–84.5) | 79.6 (64.5–89.3) | 69.5 (58.5–78.7) | 0.38 |
| 40-m walk test (sec) | 72.2 (63.7–79.4) | 81.5 (68.4–89.9) | 75.0 (56.3–87.5) | 81.3 (69.5–89.2) | 0.47 |